Foresee Pharmaceuticals Welcomes Positive CHMP Opinion Recommending Approval of CAMCEVI 21mg, 3-month strength in the European Union for Advanced Prostate Cancer
TAIPEI, March 6, 2026 /PRNewswire/ — Foresee Pharmaceuticals (6576.TWO), (“Foresee”) announced that it has received notification from its licensing partner,…
Read More







